Yuma Nato
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
悪性リンパ腫に対する二重特異性抗体抵抗性メカニズムの解明:グラフニューラルネットワークを用いた空間組織AI
Open Date: 2026-09-01
Close Date: 2027-02-01
Articles (9)
Year:
2026
Year:
2026
CD5‐positive diffuse large B‐cell lymphoma (CD5+ DLBCL) is characterized by a poor prognosis and frequent central nervous system (CNS) relapse. Sandwich therapy comprising dose‐adjusted (DA)‐EPOCH‐R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab) and high‐dose methotrexate (HD‐MTX) (DA‐EPOCH‐R/HD‐MTX) showed excellent efficacy and manageable safety in a phase II study of patients diagnosed with stage II–IV CD5+ DLBCL. To validate the results of that study and elucidate the current state of treatment for CD5+ DLBCL, we retrospectively analyzed the outcomes of patients with CD5+ DLBCL diagnosed between 2016 and 2021 who received anthracycline‐containing chemotherapy with rituximab. Among the 346 patients evaluated, 62 (18%) received DA‐EPOCH‐R/HD‐MTX. The median follow‐up time was 43 months. In 55 patients with stage II–IV disease treated with DA‐EPOCH‐R/HD‐MTX, the 2‐year overall survival (OS), progression‐free survival, and cumulative incidence of CNS relapse were 87% (95% CI, 73%–94%), 76% (95% CI, 61%–86%), and 7.3% (95% CI, 2.4%–16%), respectively. There were no treatment‐related deaths. Febrile neutropenia occurred in 18 (33%) patients. Multivariate analysis of the 346 patients identified elevated serum lactate dehydrogenase levels, multiple extranodal involvement, no intrathecal MTX (IT‐MTX), and no DA‐EPOCH‐R/HD‐MTX as independent risk factors for OS. Only one CNS relapse event was observed in 28 patients who received both HD‐MTX and IT‐MTX. Our study provides real‐world data on the treatments and outcomes of a large number of patients. The favorable survival and manageable toxicity of DA‐EPOCH‐R/HD‐MTX have been validated in clinical settings. The use of HD‐MTX and IT‐MTX might be effective for preventing CNS relapse in patients with CD5+ DLBCL.
Year:
2025
Year:
2024
Background . Autoimmune hemolytic anemia (AIHA) associated with solid tumors such as mature cystic teratomas is rare and poorly understood. Here, we report a successfully treated case of secondary AIHA in a mature cystic teratoma containing antibodies against red blood cells. Case description . A 22-year-old woman was referred to our hospital with progressive anemia. Laboratory findings revealed hemolysis with a positive direct and indirect antiglobulin test. Imaging studies identified a left ovarian mass, suspected to be a mature cystic teratoma, which was later confirmed by histopathology after laparoscopic oophorocystectomy. The patient was treated with prednisolone, resulting in improved anemia. To examine the relationship between the tumor and AIHA, an indirect antiglobulin test was performed on the tumor contents. Stronger aggregations were observed at any concentration diluted by 10 times from 10 to 10,000 times of the tumor contents compared to the patient’s serum. Additionally, immunofixation electrophoresis of the tumor contents revealed the presence of monoclonal immunoglobulin G- κ . Conclusion . The presence of monoclonal IgG- κ in the tumor suggests intratumoral antibody production as a possible mechanism. Further research is necessary to elucidate the pathogenic relationship between such tumors and AIHA. The report also highlights the importance of considering secondary AIHA in patients with unexplained anemia and solid tumors.
Year:
2024
Key Clinical Message This case of non‐nodal mantle cell lymphoma (MCL) showcases atypical hairy cell‐like features, distinguishing it via next‐generation sequencing. Despite a TP53 mutation indicating poor prognosis, our case followed an indolent course, highlighting the importance of genetic testing and phenotypical examination in MCL.
Year:
2024
Introduction: The risk of secondary central nervous system (CNS) involvement is approximately 7% in patients with extranodal natural killer/T-cell lymphoma (ENKL) who receive non-anthracycline-based chemotherapy. The prognosis of ENKL in patients who develop CNS relapse is extremely poor, and the median overall survival (OS) after CNS relapse is less than 4 months. The CNS-Prognostic Index of Natural Killer (CNS-PINK) model is widely used to predict CNS relapse (Kim H. Blood, 2020). The relationship between the number of sites of involvement and CNS relapse in ENKL remains unclear. First-line treatment approaches differ between localized and advanced ENKL. To investigate risk factors for CNS relapse in patients with ENKL, we analyzed combined data from two large retrospective studies in Japan. Methods: We retrospectively analyzed the data of patients with newly diagnosed ENKL who were diagnosed at 54 hospitals in the NKEA (2000-2013; UMIN000015491; Yamaguchi M. JCO, 2017) and NKEA-next (2014-2021; UMIN0000463000) projects. Patients without CNS involvement at diagnosis and those who had received non-anthracycline-based chemotherapy were eligible in the present study. We analyzed the following sites of involvement: the orbit, nasal cavity, paranasal sinus, cheek, gingiva, palate, and salivary grand. CNS involvement was confirmed by radiological findings, cerebrospinal fluid test results, or autopsies. The time to CNS relapse was calculated from the date of initial diagnosis of ENKL to the date of CNS relapse. In the present study, the cumulative incidence of CNS relapse was analyzed via Gray's test, with CNS relapse and death in patients without CNS involvement included as competing events. We identified risk factors for CNS relapse via Fine‒Gray regression analysis. Results: Among 708 patients with newly diagnosed ENKL, the baseline characteristics of eligible 540 patients were as follows: median age, 57 years (range, 13-86); male sex, 67%; Eastern Cooperative Oncology Group performance status (ECOG PS) > 1, 14%; and elevated serum lactate dehydrogenase level, 38%. Seventy-four % (n = 401) had localized disease, and 26% (n =139) had advanced disease. High-risk CNS-PINK was 0% in patients with localized ENKL and 81% in those of advanced ENKL. Among patients with localized ENKL, the number of sites of involvement was 0 in 9% of the patients, 1 in 65%, 2 in 19%, 3 in 6%, 4 in 0.5%, and 5 in 0.5%. As the first-line treatment, 96% of the patients with localized ENKL received chemoradiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (DeVIC), and 59% of the patients with advanced ENKL were treated with L-asparaginase-containing chemotherapy. For CNS prophylaxis, high-dose methotrexate (MTX) (≥ 2 g/m2) was used in 89 patients and intrathecal MTX or cytarabine was used in 44 patients. At a median follow-up of 52 months, 25 patients (4.6%) experienced CNS relapse. The 2-year cumulative risk of CNS relapse was 4.3% (95% CI, 2.8-6.3), and the median time to CNS relapse was 6.5 months in all patients. Nineteen patients experienced isolated CNS relapse, and 6 patients experienced concurrent systemic relapse. The incidence of CNS relapse in the brain parenchyma and leptomeninges was 26% and 74%, respectively. The 2-year cumulative risk of CNS relapse was 3.4% (95% CI, 1.9-5.5) and 7.1% (95% CI, 3.5-12) in patients with localized and advanced ENKL, respectively. Univariate analysis of the 401 patients with localized ENKL revealed that > 1 sites of involvement (P = 0.009), ECOG PS > 1 (P = 0.01), and involvement of the orbit (P = 0.007), the paranasal sinus (P = 0.006), the gingiva (P = 0.004), and the palate (P = 0.02) were identified as risk factors for CNS relapse. Multivariate analysis of patients with localized ENKL identified > 1 sites of involvement (P = 0.01) and ECOG PS > 1 (P = 0.02) as independent risk factors for CNS relapse. For patients with advanced ENKL, univariate analysis revealed that involve
Year:
2024
Year:
2023
Year:
2023
Collaborators (1)
Keiki Nagaharu
Lund University
Make your next move.
Prepare your application
Review drafts before you send them.